|
|
 |
 |
|
|
|
Every year, more than 10 million people find themselves grappling with the medical uncertainties and emotional upheaval of a newly diagnosed cancer. Fortunately, an increasing number of patients benefit from surgery, radiation and medicines, but still there is recurrence of the disease. Thus, there remains a therapeutic gap to be bridged with innovative and improved treatments that enhances the quality of life.
No other area of biomedicine has profited more from the Human Genome Project than cancer biology, with deep insights into the fundamentals of how gene mutations and faulty cellular circuitry lie behind the aberrant growth, invasion, and metastasis of cancerous tissues in the body.
|
|
|
 |
|
Armed with such insights, we have embarked on a major drive to discover and develop innovative medicines for some of the most common cancers. Cutting-edge research conducted at Boehringer Ingelheim Austria has resulted in promising drug candidates moving into clinical development at our Biberach site.
|
| A novel type of triple angiokinase inhibitor, targeting
endothelial cell receptors responsible for cancer
neo-angiogenesis, Vargatef™ (BIBF 1120) is planned to enter phase III clinical
development in 2008. A dual kinase inhibitor targeting epidermal
growth factor receptor and HER2 kinase, Tovok™ (BIBW 2992), has shown promising
results in patients with advanced solid tumours. Tovok™ is planned to enter III clinical trials in 2008, too. And
further, a first-in-class cell cycle/ polo-like kinase 1
inhibitor was applied in a single dose escalation study to
patients with advanced solid malignancies. In addition, we
are increasing our efforts in monoclonal antibody based projects for treatment of both solid and haematological
neoplasias. |
|
|
|
© 1999 Boehringer
Ingelheim GmbH, Germany. All rights reserved.
Imprint | Terms
of use
Last update: 08.04.2008
|
|
|
|
